Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) PT at $41.00

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) have been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $41.00.

Several equities analysts have weighed in on the stock. Piper Sandler assumed coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, January 7th. They set an “overweight” rating and a $40.00 price objective on the stock. Oppenheimer raised their target price on Olema Pharmaceuticals from $45.00 to $48.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. UBS Group initiated coverage on Olema Pharmaceuticals in a report on Wednesday, January 7th. They set a “buy” rating and a $45.00 price target on the stock. HC Wainwright increased their price objective on Olema Pharmaceuticals from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Thursday, January 22nd.

Olema Pharmaceuticals Price Performance

NASDAQ OLMA opened at $25.36 on Friday. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01. Olema Pharmaceuticals has a 1 year low of $2.86 and a 1 year high of $36.26. The company has a market cap of $1.74 billion, a PE ratio of -13.56 and a beta of 1.89. The stock’s 50-day moving average price is $27.43 and its two-hundred day moving average price is $15.64.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Monday, November 10th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.05). On average, analysts predict that Olema Pharmaceuticals will post -2.33 EPS for the current year.

Insider Activity at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, insider Shane William Charles Kovacs sold 100,000 shares of Olema Pharmaceuticals stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $28.73, for a total transaction of $2,873,000.00. Following the completion of the sale, the insider owned 139,727 shares of the company’s stock, valued at $4,014,356.71. This trade represents a 41.71% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Naseem Zojwalla sold 99,509 shares of the business’s stock in a transaction on Tuesday, December 23rd. The shares were sold at an average price of $27.66, for a total transaction of $2,752,418.94. Following the transaction, the insider owned 4,488 shares in the company, valued at approximately $124,138.08. This represents a 95.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 765,501 shares of company stock valued at $22,052,432. 16.36% of the stock is owned by company insiders.

Institutional Trading of Olema Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. grew its stake in Olema Pharmaceuticals by 55.4% in the second quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock valued at $26,000 after purchasing an additional 2,168 shares in the last quarter. Farther Finance Advisors LLC grew its stake in shares of Olema Pharmaceuticals by 602.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company’s stock valued at $29,000 after buying an additional 5,866 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in Olema Pharmaceuticals by 9,476.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after buying an additional 1,232 shares during the last quarter. FNY Investment Advisers LLC raised its position in Olema Pharmaceuticals by 100.0% during the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock valued at $42,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Torren Management LLC bought a new position in Olema Pharmaceuticals during the fourth quarter valued at approximately $44,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.